Insmed's Brensocatib Receives the US FDA's Breakthrough Therapy Designation to Treat Non-Cystic Fibrosis Bronchiectasis
Shots:
- The BTD is based on P-II WILLOW study assessing brensocatib vs PBO in adults with NCFBE for reducing exacerbations
- Insmed expects to initiate a P-III program for brensocatib in bronchiectasis in the H2’21
- Brensocatib is a novel oral- reversible DPP1 inhibitor- currently being developed for the treatment of bronchiectasis and other inflammatory diseases
Ref: PRNewswire | Image: Twitter
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
